BGPT: Paper Review: Glucagon receptors along the nephron: [125I]glucagon binding in rat tubules

Explore by Goal

Quick Explanation Copied

Core finding

In microdissected rat nephron segments, specific [125I]glucagon binding is detected only in segments that contain glucagon-sensitive adenylate cyclase activity—notably medullary thick ascending limb (MAL) and distal convoluted tubule (DCT) (high binding), with lower binding in collecting tubule; binding is not detected in proximal tubule or thin Henle’s segments.

Key quantitative anchors

KD (MAL, Scatchard): ~2.4 nM
Specific binding magnitude at 7.5 nM: 16–27 amol·mm⁻¹ (MAL) and in DCT; 2–5 amol·mm⁻¹ (collecting tubule); not detected (PCT; thin Henle’s).
Specificity: glucagon displaces labeled ligand (stronger than enteroglucagon); vasopressin, calcitonin, PTH, insulin do not.

Long Explanation

Paper Review (visual, critical): Glucagon receptors along the nephron: [125I]glucagon binding in rat tubules

Butlen & Morel (Pflügers Archiv / European Journal of Physiology), DOI: 10.1007/BF00585347

What the paper actually measures (and what it cannot prove)

Measured: Radioligand binding of [125I]glucagon to microdissected nephron segments, with non-specific binding estimated by adding unlabeled glucagon (5 µM) during the reaction start.
Found: Specific binding is segment-restricted and correlates with glucagon-sensitive adenylate cyclase activity.
Cannot directly prove here: that the detected binding is mediated by a particular gene-defined receptor protein (the paper uses binding-kinetics/pharmacology rather than molecular receptor identification).

VISUALIZATION 1 — Tubule length scaling (MAL)

Regression equations are taken verbatim from the paper figure description for Fig. 1.

VISUALIZATION 2 — Equilibrium association/dissociation qualitative constraints (MAL)

Interpretation guardrail

The paper reports time-dependent reversibility: glucagon displacement is near-complete when initiated shortly after binding starts, but is only partial when displacement is initiated after longer pre-incubation.

VISUALIZATION 3 — Scatchard linear transform (MAL)

Scatchard equation and linearity are from the Fig. 3 description.

VISUALIZATION 4 — Segment specificity (bar chart using paper-reported ranges)

Reported ranges at 7.5 nM: high specific binding (16–27 amol·mm⁻¹) in MAL and DCT, lower specific binding (2–5) in collecting tubule, and not detected in PCT and thin Henle’s segments.

VISUALIZATION 5 — Competition specificity: glucagon vs enteroglucagon (conceptual)

What the paper claims

In MAL and MCT, glucagon displaces labeled glucagon more effectively than enteroglucagon (oxyntomodulin). The paper reports apparent dissociation constants for enteroglucagon displacement: ~0.4 pM (MAL) and ~0.7 pM (MCT).

It further states that vasopressin, calcitonin, PTH, and insulin produce no detectable inhibition of [125I]glucagon binding in MAL and MCT.

Mechanistic logic (and where it might be overextended)

What supports the “physiological receptor” interpretation

Pharmacological concordance: segment-restricted binding matches the paper’s prior mapping of glucagon-sensitive adenylate cyclase activity (same nephron segments).
Kinetic/pharmacological receptor-like behavior: the authors report concentration dependence, Scatchard linearity, a finite KD estimate (~2.4 nM in MAL), and stereospecific competition (glucagon > enteroglucagon; unrelated hormones inactive).

Critical skeptical checks (possible blind spots)

Non-specific binding definition details are internally concerning in the provided text. The methods text (as pasted) says non-specific binding is measured with “5 pM unlabelled glucagon,” but the context of competition assays typically uses much higher concentrations for non-specific blocking. Because this value appears inconsistent with the paper’s broader narrative and standard radioligand practice, it could meaningfully affect the “specific binding” subtraction and thus segment differences.
Ligand internalization/down-regulation is invoked but not directly measured. The authors suggest that time-dependent reversibility might reflect an internalization process/down-regulation seen for other peptide hormones. In this paper, the provided text does not show direct receptor trafficking quantification in nephron segments (e.g., microscopy/endosomal fractionation), so the mechanistic step remains inferential.
Unit/scale ambiguity may affect quantitative comparisons. The abstract-like text in the prompt uses “16–27x10 -18 mol mm-~” style units. The visualization uses the numerical ranges only; exact unit consistency is not fully verifiable from the pasted fragment.

What you should take away (with confidence levels)

High confidence

The study provides evidence that detectable specific glucagon binding is restricted to particular nephron segments and that binding is pharmacologically stereospecific versus unrelated peptide hormones.

Moderate confidence

The conclusion that these binding sites are the physiological glucagon receptors responsible for adenylate cyclase activation is plausible because of concordant distribution and KD matching discussed by the authors, but the causality (binding → signaling in the same tissue context) is not directly shown in the provided text.

Lower confidence / potential red flags

The precise non-specific binding competitor concentration/unit in the pasted methods text could matter substantially; if it is mis-copied, “specific” binding subtraction could change.

Buttons for deeper BGPT follow-ups

Author reviews (BGPT)

Feedback:

Updated: May 02, 2026